Hiroaki Akamatsu
Wakayama Medical University(JP)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- → Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer(2023)601 cited
- → Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer(2023)417 cited
- → Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab(2017)376 cited
- → Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis(2020)271 cited
- → Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer(2021)194 cited
- → Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor(2021)180 cited
- → Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer(2014)178 cited
- → Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System(2013)175 cited
- → Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors(2020)171 cited